Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study - AIO SUP-0108. [electronic resource]
Producer: 20170721Description: 127-34 p. digitalISSN:- 1879-0852
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- administration & dosage
- Antineoplastic Agents -- administration & dosage
- Ascites -- drug therapy
- Bevacizumab -- administration & dosage
- Double-Blind Method
- Female
- Gastrointestinal Neoplasms -- complications
- Humans
- Injections, Intraperitoneal
- Male
- Middle Aged
- Survival Analysis
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.